Abstract
Commentary on the latest phase 2 results of crizanlizumab, a novel pharmaceutical agent for the prevention of vaso-occlusive crises in patients suffering from sickle cell disease.
| Original language | American English |
|---|---|
| Journal | Practical Pain Management |
| DOIs | |
| State | Published - Dec 2016 |
Disciplines
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS